Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

nipocalimab-aahu (Imaavy)

nipocalimab-aahu is an FDA-licensed reference biologic from Janssen Biotech, Inc..

351(a) biologicBLA 761430 Janssen Biotech, Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2025

Reference product

Originator biologic
351(a)BLA 761430

Imaavy nipocalimab-aahu

Janssen Biotech, Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CDER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for nipocalimab-aahu from the RCSB Protein Data Bank (PDB 9MI6).

3D molecular structure of nipocalimab-aahu (PDB entry 9MI6)

Interactive biological assembly from PDB entry 9MI6. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference nipocalimab-aahu product.

    1 yr 5 mo ago

nipocalimab-aahu: frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for nipocalimab-aahu.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.